Last reviewed · How we verify
Afuresertib GC - Fed State — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Afuresertib GC - Fed State (Afuresertib GC - Fed State) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Afuresertib GC - Fed State TARGET | Afuresertib GC - Fed State | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Afuresertib GC - Fed State CI watch — RSS
- Afuresertib GC - Fed State CI watch — Atom
- Afuresertib GC - Fed State CI watch — JSON
- Afuresertib GC - Fed State alone — RSS
Cite this brief
Drug Landscape (2026). Afuresertib GC - Fed State — Competitive Intelligence Brief. https://druglandscape.com/ci/afuresertib-gc-fed-state. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab